<DOC>
	<DOCNO>NCT01885663</DOCNO>
	<brief_summary>This open label trial conduct investigate efficacy safety allogeneic umbilical cord blood ( UCB ) therapy patient acquire brain injury .</brief_summary>
	<brief_title>UCB Therapy Acquired Brain Injury</brief_title>
	<detailed_description>Acquired brain injury ( ABI ) mean brain damage cause event birth , rather part genetic congenital disorder . Those ABI suffer cognitive , physical , behavioral impairment limit activity participation society . ABI result traumatic non-traumatic brain injury due internal external source ( e.g . infection , brain tumor , hypoxia ) . Preclinical study regard cell therapy animal model ABI show improvement neurological dysfunction . UCB posse various stem progenitor cell know secrete neurotrophic factor repair injured brain . This clinical research aim determine safety efficacy allogeneic UCB patient ABI .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>Acquired brain injury Duration : 12 month Willing comply study procedure Medical instability include pneumonia renal function enrollment Uncontrolled persistent epilepsy Poor cooperation guardian , include inactive attitude rehabilitation visit followup Not eligible accord principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Umbilical cord blood</keyword>
	<keyword>Acquired brain injury</keyword>
</DOC>